OnabotulinumtoxinA Dosing, Disease Severity, and Treatment Benefit in Patients With Cervical Dystonia: A Cohort Analysis From CD PROBE

OnabotulinumtoxinA Dosing, Disease Severity, and Treatment Benefit in Patients With Cervical Dystonia: A Cohort Analysis From CD PROBE

IntroductionThe Cervical Dystonia Patient Registry for Observation of OnabotulinumtoxinA Efficacy (CD PROBE) study (ClinicalTrials.gov identifier: NCT00836017), a multicenter, prospective, observational registry, was designed to identify real-world practices and outcomes for patients with cervical d...

Full description

Bibliographic Details
Main Authors: Pinky Agarwal, Richard Barbano, Henry Moore, Marc Schwartz, Aleksej Zuzek, Marjan Sadeghi, Atul Patel
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-06-01
Series:Frontiers in Neurology
Subjects:
cervical dystonia
onabotulinumtoxinA
treatment benefit
disease severity
dosing
Online Access:https://www.frontiersin.org/articles/10.3389/fneur.2022.914486/full

Internet

https://www.frontiersin.org/articles/10.3389/fneur.2022.914486/full

Similar Items